• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

    9/27/23 9:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email

    Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)

    "Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support," said Mr. Stapley. "His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world."

    Dr. Febbo has more than 25 years of experience across academia and industry. He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers. Prior to that, he was chief medical officer for Genomic Health, where he oversaw the development and expansion of the company's test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement. Before Genomic Health, Dr. Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA). Dr. Febbo holds a B.A. in Biology from Dartmouth College and earned his M.D. from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute.

    "Cancer mortality rates have started to improve due to better detection and management. Veracyte has distinguished itself with its high-performing tests that are helping physicians use underlying biology of an individual's cancer to make personalized management decisions that improve patient outcomes and healthcare efficiencies," said Dr. Febbo. "I am thrilled to join the company's talented team and to help advance the future of insight-driven care."

    About Veracyte

    Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "positioned," "designed" and similar references to future periods. Examples of forward-looking statements include, among others, that Dr. Febbo will help advance novel tests that address important unmet patient-care needs in cancer. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230927846710/en/

    Get the next $VCYT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

    Veracyte, Inc. (NASDAQ:VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure pat

    8/29/25 8:30:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

    Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial Veracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity. The findings—from the randomized, prospective, Phase 3 STAMPEDE trial—are the first to be published showing that a gene expression test can help clinicians better personalize chemotherapy decisions for pat

    8/27/25 11:25:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test. The milestone marks an important step in Veracyte's goal of making the novel molecular test widely available and helping clinicians to better guide next steps for patients with potentially cancerous lung nodules. "Demonstrating that a new test can positively impact patient care is key for physician adoption and health insurer coverage," said Bill Bulman, M.D., Veracyte's medical director for Pulmonology. "We are delighted to complete enrollment for NIGHTINGALE, which we

    8/26/25 8:30:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

    SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

    8/12/25 10:34:25 AM ET
    $VCYT
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Veracyte Inc.

    10-Q - VERACYTE, INC. (0001384101) (Filer)

    8/7/25 4:41:08 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VERACYTE, INC. (0001384101) (Filer)

    8/6/25 4:08:41 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Stapley Marc sold $233,133 worth of shares (7,667 units at $30.41), decreasing direct ownership by 2% to 334,185 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    9/8/25 4:33:36 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Chief Financial Officer Chambers Rebecca covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 4% to 133,158 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    9/4/25 5:45:15 PM ET
    $VCYT
    Medical Specialities
    Health Care

    SVP, General Counsel Mcguire Annie covered exercise/tax liability with 3,507 shares, decreasing direct ownership by 4% to 93,882 units (SEC Form 4)

    4 - VERACYTE, INC. (0001384101) (Issuer)

    9/4/25 5:18:05 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Veracyte with a new price target

    Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

    3/20/25 7:42:48 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte downgraded by Goldman with a new price target

    Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously

    12/5/24 8:24:30 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Wolfe Research initiated coverage on Veracyte with a new price target

    Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00

    11/15/24 8:25:09 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veracyte Inc.

    SC 13G - VERACYTE, INC. (0001384101) (Subject)

    11/12/24 9:30:49 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    11/8/24 10:41:07 AM ET
    $VCYT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

    SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

    10/2/24 2:12:30 PM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    View All

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

    9/4/24 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

    Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

    9/27/23 9:00:00 AM ET
    $VCYT
    Medical Specialities
    Health Care

    $VCYT
    Financials

    Live finance-specific insights

    View All

    Veracyte Announces Second Quarter 2025 Financial Results

    Grew total revenue to $130.2 million and testing revenue to $122.3 million, representing increases of 14% year-over-year Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. "Testing growth continues to exceed our expectations, driven by Decipher which achieved its thirteenth consecutive quarter of over 25% year-over-year volume growth," said Marc Stapley, Veracyte's chief executive officer. "This strong result, combined with Afirma volume meeting our expectations and the resolution of the French subsidiary proceedings, has positioned us for in

    8/6/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5gqvvmtt. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte

    7/17/25 5:30:00 PM ET
    $VCYT
    Medical Specialities
    Health Care

    Veracyte Announces First Quarter 2025 Financial Results

    Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

    5/7/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care